Eli Lilly’s Weight-Loss Pill Wins FDA Approval
Culture Index
Score Breakdown
Relevance
9/25
Freshness
13/25
Authority
25/20
Brand Signal
6/15
Depth
2/15
5-Axis Cultural Radar
Orforglipron, which will be sold under the brand name Foundayo, becomes the second GLP-1 weight-loss pill to enter the US market after Novo Nordisk’s tablet-form Wegovy launched in Jan. 2026.
